Business UpdateJun 2, 2026, 08:32 AM
bioAffinity: SAB to host webinar on CyPath Lung's role in lung cancer detection
AI Summary
bioAffinity Technologies announced that the Society for Advanced Bronchoscopy (SAB) will host a webinar on June 16, 2026, focusing on the expanding role of its noninvasive CyPath® Lung test. The webinar will feature a multidisciplinary physician panel discussing how CyPath® Lung aids in early-stage lung cancer detection, supports treatment decisions, reduces healthcare costs, and assists in post-treatment surveillance. The test has shown high sensitivity and specificity in clinical trials for high-risk patients.
Key Highlights
- Society for Advanced Bronchoscopy (SAB) to host a webinar on bioAffinity Technologies' CyPath® Lung test.
- The webinar, titled "Navigating Lower Cancer-Risk Nodules in High-Risk Patients with Noninvasive CyPath® Lung Testing," is scheduled for June 16.
- A multidisciplinary physician panel will discuss CyPath® Lung's benefits in pulmonary, oncology, and surgical practices.
- CyPath® Lung aids in early lung cancer detection, supports treatment decisions, and lowers healthcare costs.
- The test demonstrated 92% sensitivity, 87% specificity, 88% accuracy, and 99% negative predictive value in a clinical trial.
- CyPath® Lung uses automated flow cytometry and artificial intelligence to analyze the lung microenvironment.
Price Impact
More from BIAF